Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Cash & Current Investments: 2022-2024

Historic Cash & Current Investments for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Dec 2024 value amounting to $482.2 million.

  • Centessa Pharmaceuticals' Cash & Current Investments fell 52.51% to $246.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 2.80%. This contributed to the annual value of $482.2 million for FY2024, which is 87.95% up from last year.
  • Per Centessa Pharmaceuticals' latest filing, its Cash & Current Investments stood at $482.2 million for FY2024, which was up 87.95% from $256.5 million recorded in FY2023.
  • Centessa Pharmaceuticals' 5-year Cash & Current Investments high stood at $482.2 million for FY2024, and its period low was $256.5 million during FY2023.
  • In the last 3 years, Centessa Pharmaceuticals' Cash & Current Investments had a median value of $393.6 million in 2022 and averaged $377.5 million.
  • As far as peak fluctuations go, Centessa Pharmaceuticals' Cash & Current Investments crashed by 34.83% in 2023, and later skyrocketed by 87.95% in 2024.
  • Over the past 3 years, Centessa Pharmaceuticals' Cash & Current Investments (Yearly) stood at $393.6 million in 2022, then plummeted by 34.83% to $256.5 million in 2023, then soared by 87.95% to $482.2 million in 2024.